| Literature DB >> 28890077 |
Catherine E Stewart1, Merrick J Moseley2, Pantelis Georgiou3, Alistair R Fielder2.
Abstract
Occlusion therapy remains the mainstay treatment of amblyopia, but its outcome is not assured or universally excellent. Many factors are known to influence treatment outcome, among which compliance is foremost. The occlusion dose monitor (ODM) removes one variable from the treatment equation, because it records the occlusion actually received by-rather than prescribed for-the child. Improvement observed can thus be quantitatively related to the patching received. This review summarizes the insights the ODM has provided to date particularly in elucidating the dose-response relationship. We are entering the era of personalized ophthalmology in which treatments will be tailored to the needs of the individual child and facilitated by the use of wearable monitors.Entities:
Mesh:
Year: 2017 PMID: 28890077 DOI: 10.1016/j.jaapos.2017.06.018
Source DB: PubMed Journal: J AAPOS ISSN: 1091-8531 Impact factor: 1.220